Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cell Division Protein FtsZ (ftsz) - Overview
Cell Division Protein FtsZ (ftsz) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cell Division Protein FtsZ (ftsz) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cell Division Protein FtsZ (ftsz) - Companies Involved in Therapeutics Development
Pedanius Therapeutics Ltd
TAXIS Pharmaceuticals Inc
Cell Division Protein FtsZ (ftsz) - Drug Profiles
PED-012 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBP-17GA20 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit ftsz for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit FtsZ for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit FtsZ for Streptococcal Pneumonia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit FtsZ for Tuberculosis - Drug Profile
Product Description
Mechanism Of Action
TXA-709 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cell Division Protein FtsZ (ftsz) - Dormant Products
Cell Division Protein FtsZ (ftsz) - Product Development Milestones
Featured News & Press Releases
Dec 13, 2019: Pedanius Therapeutics FtsZ Programme demonstrates in vivo efficacy in pneumonia caused by Acinetobacter baumannii
Sep 07, 2016: FDA Grants Special Desigtion to TAXIS Pharmaceuticals Experimental Antibiotic:
Jun 13, 2016: Experimental Antibiotic Treats Deadly MRSA Infection
Sep 18, 2015: TAXIS Pharmaceuticals Demonstrates Synergistic Efficacy Against MRSA And Low Resistance Frequency With TXA709/Cefdinir Combition
Jun 05, 2015: TAXIS Pharmaceuticals Announces Publication of Data Demonstrating Potential Viability of TXA709 in Combating Antibiotic Resistance
Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Pedanius Therapeutics Ltd, 2022
Pipeline by TAXIS Pharmaceuticals Inc, 2022
Dormant Projects, 2022